<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63888">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02274194</url>
  </required_header>
  <id_info>
    <org_study_id>CEP 102/13</org_study_id>
    <nct_id>NCT02274194</nct_id>
  </id_info>
  <brief_title>Type of Breathing and CPAP on Patients With Obstructive Sleep Apnea</brief_title>
  <official_title>Nasal, Oral, Oronasal Breathing and CPAP on Nasal Mucociliary Clearance, Mucus Properties, Cytokines in Nasal Lavage and Exhaled Breath Condensate pH of Patients With Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The obstructive sleep apnea (OSA) affects between 10% to 25% of the adults. Continuous
      positive airway pressure (CPAP) is the chosen treatment in moderate and severe OSA. However,
      the adherence to CPAP varies, and the interface between patient and the CPAP may interfere
      with adherence, comfort and efficiency. Objectives: (1) to determine which is the preferred
      airway flow in oral and nasal breathers, (2) to analyze the role of body position on the
      nasal mucosa and the airways after one night CPAP titration, (3) the effects of nasal and
      oronasal CPAP on the nasal epithelium and airways, inflammation in nasal lavage and miRNA
      changes in blood and (4) CPAP adherence after 12 months. Population: 20 patients with
      moderate/severe OSA recruited at Sleep Laboratory of Heart Institute - Hospital das Clínicas
      da Faculdade de Medicina da Universidade de São Paulo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After agreement with the written informed consent, 40 volunteers (10 healthy volunteers and
      20 OSA patients) male and female, aged &gt;21 years will be recruited in the Laboratory of
      Sleep of the Clinics Hospital and int the School of Medicine. The volunteers will be
      evaluated in the laboratory of Sleep (Incor) seven times (T). First Phase: volunteers will
      be assessed for breathing route and assigned to two groups: Group Nasal Breather and oral or
      oronasal breather. Second: CPAP titration. Third phase: use of CPAP during 30 days after
      CPAP titration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apnea-Hypopnea Index</measure>
    <time_frame>Baseline (Time 0)</time_frame>
    <description>A full-night diagnostic polysomnography will be performed in each subject. To determine the stages of sleep, an electroencephalogram, electro-oculogram and electromyogram of the submentalis muscle will be obtained. Arterial blood oxyhaemoglobin will record with the use of a finger pulse oximeter. Thoracoabdominal excursions will measure qualitatively using respiratory effort sensors placed over the ribcage and abdomen. Snoring will be detected with a vibration snore sensor and body posture with a body position sensor. Subjects will use a molded single-piece translucent silicone rubber mask,</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CPAP level</measure>
    <time_frame>CPAP titration</time_frame>
    <description>Using two full-nights polysomnography for CPAP titration. To determine the appropriate CPAP level with nasal and oronasal masks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Airway inflammation by exhaled breath condensate pH and cytokines</measure>
    <time_frame>Participants will be assessed at baseline (Time 0), nasal titration (first week), oronasal titration and nasal CPAP (30 days)</time_frame>
    <description>The EBC sample is collected over 15 min of quiet and normal breathings (regular tidal volumes and respiratory rate) through a mouthpiece that is connected to a collector device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal mucociliary clearance by saccharine transit time</measure>
    <time_frame>Participants will be assessed at at baseline (Time 0), nasal titration (first week), oronasal titration and nasal CPAP (30 days)</time_frame>
    <description>We evaluate the nasal MCC by measuring nasal saccharine transport time (STT). The subject is asked to avoid alcohol, tea and coffee for 6 hours and to eat or drink nothing for 2 hours before the measurements. The STT assessment is performed in a quiet room at a temperature of 21-22ºC and relative humidity of 63-71%. Subjects sat in a chair and are asked to maintain regular breathing, to avoid deep breathing, coughing, sneezing, sniffing or talking during STT measurements. Twenty-five µg saccharin particles are deposited 2 cm from the anterior end of the non-obstructed nostril and the timer is stopped at the first perception of sweet taste. The maximum delay between the deposition and perception is set at 60 minutes for non-detection.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Inflammation by cytokines in nasal lavage</measure>
    <time_frame>Participants will be assessed at at baseline (Time 0), nasal titration (first week), oronasal titration and nasal CPAP (30 days)</time_frame>
    <description>TNF-α, IL-1beta, IL-6, IL-8, IL-10, IL-13, IL-17, MPO, MIPs, MMPs (multiplex bead assay and ELISA) in nasal lavage.</description>
  </other_outcome>
  <other_outcome>
    <measure>miRNAs expression</measure>
    <time_frame>Patients will be assessed at baseline and after 30-days of treatment (CPAP)</time_frame>
    <description>Blood sample will be collected in paxgene tube (BD do Brasil, SP, Brasil). MicroRNAs will be extracted from the blood samples. PCR Array will be customized (Custom miScript miRNA PCR Array, Qiagen Inc., Valencia, USA) for the miRNAs analysis.</description>
  </other_outcome>
  <other_outcome>
    <measure>Sleep quality by Pittsburg questionnaire</measure>
    <time_frame>Participants will be assessed at at baseline (Time 0), nasal titration (first week), oronasal titration and nasal CPAP (30 days)</time_frame>
    <description>It is a questionnaire to assess the quality of sleep (basically 7 components)</description>
  </other_outcome>
  <other_outcome>
    <measure>Upper airways symptoms by SNOT20 questionnaire</measure>
    <time_frame>Participants will be assessed at at baseline (Time 0) and nasal CPAP (30 days)</time_frame>
    <description>This is a questionnaire that aims to assess quality of life of patients with chronic upper airways symptoms</description>
  </other_outcome>
  <other_outcome>
    <measure>Epworth Sleepiness Scale</measure>
    <time_frame>Participants will be assessed at at baseline (Time 0) and nasal CPAP (30 days)</time_frame>
    <description>This is a questionnaire about daytime sleepiness with 8 questions.</description>
  </other_outcome>
  <other_outcome>
    <measure>CPAP adherence</measure>
    <time_frame>one-year follow up</time_frame>
    <description>CPAP adherence will be investigated after one-year</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Nasal CPAP followed by oronasal CPAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group nasal mask: use of CPAP for one night whit wash out one week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oronasal CPAP followed by nasal CPAP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group oronasal mask: use of CPAP for one night with wash out one week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>After polysomnography they will be under investigation for breathing route (nasal, oronasal or both)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nasal CPAP</intervention_name>
    <description>use of nasal mask to titrate CPAP - after titration 30 days of nasal CPAP</description>
    <arm_group_label>Nasal CPAP followed by oronasal CPAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oronasal CPAP</intervention_name>
    <description>use of oronasal mask to titrate CPAP - after titration 30 days of nasal CPAP</description>
    <arm_group_label>Oronasal CPAP followed by nasal CPAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;21 years

          -  moderate or severe obstructive sleep apnea

          -  nonsmokers

          -  ex smokers (cessation &gt;12 months)

        Exclusion Criteria:

          -  infection / acute respiratory inflammation (30 days after to study entry)

          -  fixed nasal obstruction diagnosed

          -  nasal or upper airways surgery

          -  chronic diseases without optimized treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naomi K Nakagawa, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Naomi K Nakagawa, PhD</last_name>
    <phone>+551130618529</phone>
    <email>naomi.kondo@usp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juliana A Nascimento</last_name>
    <phone>+551130618529</phone>
    <email>juliananascimento@usp.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto do Coração -HCFMUSP</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naomi K Nakagawa, PhD</last_name>
      <phone>+551130618529</phone>
      <email>naomi.kondo@usp.br</email>
    </contact>
    <contact_backup>
      <last_name>Geraldo Lorenzi Filho, PhD</last_name>
      <phone>+551126615486</phone>
      <email>geraldo.lorenzi@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Geraldo Lorenzi Filho, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Naomi K Nakagawa, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 7, 2015</lastchanged_date>
  <firstreceived_date>September 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Naomi Kondo Nakagawa</investigator_full_name>
    <investigator_title>Associate Professor of Physiotherapy</investigator_title>
  </responsible_party>
  <keyword>CPAP</keyword>
  <keyword>Nasal mask</keyword>
  <keyword>Oronasal mask</keyword>
  <keyword>Mucociliary clearance</keyword>
  <keyword>breathing route</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Respiratory Aspiration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
